Log in

TSE:GUDKnight Therapeutics Stock Price, Forecast & News

C$6.80
-0.01 (-0.15 %)
(As of 07/10/2020 08:34 AM ET)
Add
Compare
Today's Range
C$6.75
Now: C$6.80
C$6.87
50-Day Range
C$6.81
MA: C$7.22
C$7.64
52-Week Range
C$4.73
Now: C$6.80
C$8.88
Volume93,794 shs
Average Volume360,596 shs
Market CapitalizationC$920.60 million
P/E Ratio136.00
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.
Read More
Knight Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-484-4483

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$90.34 million
Cash FlowC$3.86 per share
Book ValueC$5.87 per share

Profitability

Miscellaneous

Employees27
Market CapC$920.60 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive GUD News and Ratings via Email

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Knight Therapeutics (TSE:GUD) Frequently Asked Questions

How has Knight Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Knight Therapeutics' stock was trading at C$6.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GUD shares have increased by 12.6% and is now trading at C$6.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Knight Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Knight Therapeutics.

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Knight Therapeutics.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc (TSE:GUD) issued its quarterly earnings data on Friday, June, 26th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.13. The company earned $45.84 million during the quarter, compared to analysts' expectations of $60.35 million. View Knight Therapeutics' earnings history.

What price target have analysts set for GUD?

4 analysts have issued 12 month price targets for Knight Therapeutics' stock. Their forecasts range from C$8.00 to C$10.25. On average, they anticipate Knight Therapeutics' share price to reach C$8.83 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price. View analysts' price targets for Knight Therapeutics.

Has Knight Therapeutics been receiving favorable news coverage?

Press coverage about GUD stock has trended neutral recently, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Knight Therapeutics earned a news impact score of 0.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Knight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

What other stocks do shareholders of Knight Therapeutics own?

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the following people:
  • Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)
  • Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
  • Mr. Michel Loustric, Pres of Knight Barbados
  • Ms. Amal Khouri, VP of Bus. Devel.
  • Ms. Jody Engel, Director of Bus. Devel.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$6.80.

How big of a company is Knight Therapeutics?

Knight Therapeutics has a market capitalization of C$920.60 million and generates C$90.34 million in revenue each year. Knight Therapeutics employs 27 workers across the globe.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is www.gud-knight.com.

How can I contact Knight Therapeutics?

The company can be reached via phone at 514-484-4483.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.